ダウンロード数 : ?
ファイル
言語
英語
著者
片倉 賢紀
橋本 道男
井上 貴之 島根大学総合理工学部
Abdullah Al Mamun
Iwamoto, Ryo Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo
Arita, Makoto Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo,
Tsuchikura, Satoru Disease Model Cooperative Research Association, Hamamatsu, Shizuoka
内容記述(抄録等)
The omega-3 polyunsaturated fatty acids (ω-3 PUFAs) docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA) protect against diabetic nephropathy by inhibiting inflammation. The aim of this study was to assess the effects of highly purified DHA and EPA or EPA only administration on renal function and renal eicosanoid and docosanoid levels in an animal model of metabolic syndrome, SHR.Cg-Leprcp/NDmcr (SHRcp) rats. Male SHRcp rats were divided into 3 groups. Control (5% arabic gum), TAK-085 (300 mg/kg/day, containing 467 mg/g EPA and 365 mg/g DHA), or EPA (300 mg/kg/day) was orally administered for 20 weeks. The urinary albumin to creatinine ratio in the TAK-085-administered group was significantly lower than that in other groups. The glomerular sclerosis score in the TAK-085-administered group was significantly lower than that in the other groups. Although DHA levels were increased in total kidney fatty acids, the levels of nonesterified DHA were not significantly different among the 3 groups, whereas the levels of protectin D1, resolvin D1, and resolvin D2 were significantly increased in the TAK-085-administered group. The results show that the use of combination therapy with DHA and EPA in SHRcp rats improved or prevented renal failure associate with metabolic syndrome with decreasing triglyceride levels and increasing ω-3 PUFA lipid mediators.
主題
protectin
resolvin
lipidomics
diabetic nephropathy
掲載誌名
Molecules
19
3
開始ページ
3247
終了ページ
3263
ISSN(Online)
1420-3049
DOI
PubMed ID
出版者
MDPI (Basel, Switzerland)
資料タイプ
学術雑誌論文
ファイル形式
PDF
著者版/出版社版
出版社版
業績ID
e27660
部局
医学部
このエントリーをはてなブックマークに追加